Thu. 21 Mar 2024, 9:01am ET
Benzinga
Earnings, News
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year.